The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A08 | Antiobesity preparations, excl. diet products | |
3
|
A08A | Antiobesity preparations, excl. diet products | |
4
|
A08AA | Centrally acting antiobesity products | |
5
|
A08AA62 |
| Active Ingredient |
|---|
|
The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood. Naltrexone is a mu-opioid antagonist and bupropion, a weak inhibitor of neuronal dopamine and norepinephrine reuptake. These components affect two principal areas of the brain, specifically the arcuate nucleus of the hypothalamus and the mesolimbic dopaminergic reward system. |
| Document | Type | Information Source | |
|---|---|---|---|
| CONTRAVE Extended-release tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| MYSIMBA Prolonged-release tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.